AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30920255 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion (BUP)
Number of subjects: 95
Study 30920255 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 95
Study 30920255 — intervention group
Group type: COMPARATOR
Intervention: Delayed Quit Group (DQG)
Number of subjects: 95
Study 30144037 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab 12 mg/day
Number of subjects: 0
Study 30144037 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab 24 mg/day
Number of subjects: 0
Study 30144037 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Number of subjects: 0
Study 26556571 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% octenidine mouthrinse (Octenidol®)
Number of subjects: 16
Study 26556571 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine mouthrinse (Paroex®)
Number of subjects: 16
Study 26556571 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oil mouthrinse (Listerine®)
Number of subjects: 16
Study 26556571 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthrinse
Number of subjects: 16
Study 24511232 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone long-acting injectable (RLAI)
Number of subjects: 203
Study 24511232 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 203
Study 24511232 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment group
Number of subjects: 203
Study 24511232 — intervention group
Group type: COMPARATOR
Intervention: Independent sample
Number of subjects: 203
Study 24511232 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial assessment
Number of subjects: 203
Study 24511232 — intervention group
Group type: EXPERIMENTAL
Intervention: Reanalysis of data
Number of subjects: 203
Study 22324516 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam extended-release (XR)
Number of subjects: 130
Study 22324516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 20080036 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (2-6 mg/day)
Number of subjects: 628
Study 17907484 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hexametaphosphate containing dual‐phase dentifrice (Crest Vivid White)
Number of subjects: 200
Study 17907484 — intervention group
Group type: COMPARATOR
Intervention: Marketed negative control (Colgate Cavity Protection)
Number of subjects: 200
Study 15327939 — intervention group
Group type: EXPERIMENTAL
Intervention: Character‐line Bisection Task (CLBT)
Number of subjects: 161
Study 15327939 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter‐line Bisection Task
Number of subjects: 161
Study 15327939 — intervention group
Group type: EXPERIMENTAL
Intervention: Star‐line Bisection Task
Number of subjects: 161
Study 15327939 — intervention group
Group type: COMPARATOR
Intervention: Standard solid‐line bisection
Number of subjects: 161
Study 15327939 — intervention group
Group type: COMPARATOR
Intervention: Line cancellation
Number of subjects: 161
Study 15327939 — intervention group
Group type: COMPARATOR
Intervention: Star Cancellation
Number of subjects: 161
Study 15327939 — intervention group
Group type: COMPARATOR
Intervention: Figure copying
Number of subjects: 161
Study 11559968 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP)
Number of subjects: 77
Study 11559968 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (BD)
Number of subjects: 77
Study 11559968 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) and Beclomethasone dipropionate (BD)
Number of subjects: 77
Study 9241288 — intervention group
Group type: COMPARATOR
Intervention: TRH bolus (400 micrograms)
Number of subjects: 32
Study 9241288 — intervention group
Group type: COMPARATOR
Intervention: TRH infusion (400 micrograms)
Number of subjects: 32
Study 9241288 — intervention group
Group type: COMPARATOR
Intervention: TRH (400 micrograms)
Number of subjects: 32
Study 8487062 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of the word 'cancer' vs. 'illness'
Number of subjects: 165
Study 8487062 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report vs. interview
Number of subjects: 165
Study 8487062 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambiguous instructions vs. consistent instructions
Number of subjects: 165
Study 8487062 — intervention group
Group type: COMPARATOR
Intervention: General medical and surgical patients
Number of subjects: 165
Study 3322352 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 18
Study 3322352 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release nifedipine (Adalat Retard)
Number of subjects: 18
Study 3322352 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release nifedipine (Adalat Retard) + Atenolol
Number of subjects: 18
Study 3322352 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine + Atenolol
Number of subjects: 18
Study 31264787 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive behavioural therapy (GCBT)
Number of subjects: 88
Study 30003994 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 Gy in 2 SBRT fractions
Number of subjects: 145
Study 27619827 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg long-acting octreotide once every 4 weeks for 52 weeks
Number of subjects: 62
Study 27619827 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg long-acting octreotide
Number of subjects: 62
Study 24987842 — intervention group
Group type: EXPERIMENTAL
Intervention: Method B (basket stretched out at the bottom of the stone)
Number of subjects: 65
Study 24987842 — intervention group
Group type: COMPARATOR
Intervention: Method A (basket inserted above the stone)
Number of subjects: 65
Study 24987842 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 65
Study 22447019 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin therapy
Number of subjects: 0
Study 22447019 — intervention group
Group type: COMPARATOR
Intervention: No aspirin therapy
Number of subjects: 0
Study 19910085 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous pump feeding (pump)
Number of subjects: 178
Study 19910085 — intervention group
Group type: COMPARATOR
Intervention: Intermittent bolus feeding (bolus)
Number of subjects: 178
Study 18837074 — intervention group
Group type: EXPERIMENTAL
Intervention: Expertise-based design surgical technique
Number of subjects: 0
Study 18837074 — intervention group
Group type: COMPARATOR
Intervention: Conventional design surgical technique
Number of subjects: 0
Study 16860521 — intervention group
Group type: EXPERIMENTAL
Intervention: Values clarification exercise (VCE) with summary
Number of subjects: 159
Study 16860521 — intervention group
Group type: EXPERIMENTAL
Intervention: Values clarification exercise (VCE) without summary
Number of subjects: 159
Study 16860521 — intervention group
Group type: COMPARATOR
Intervention: Control group (no VCE)
Number of subjects: 159
Study 16860521 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid with the most helpful VCE
Number of subjects: 159
Study 16860521 — intervention group
Group type: COMPARATOR
Intervention: Decision aid without the most helpful VCE
Number of subjects: 159
Study 14578140 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple HPV types detected
Number of subjects: 133
Study 14578140 — intervention group
Group type: EXPERIMENTAL
Intervention: CIN1 or CIN2 in tissues surrounding CIN3
Number of subjects: 133
Study 14578140 — intervention group
Group type: EXPERIMENTAL
Intervention: Extent of CIN1
Number of subjects: 133
Study 14578140 — intervention group
Group type: EXPERIMENTAL
Intervention: ASC‐US/LSIL cell counts
Number of subjects: 133
Study 14578140 — intervention group
Group type: COMPARATOR
Intervention: ASC‐H/HSIL cell counts
Number of subjects: 133
Study 11130130 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 30
Study 11130130 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible Laryngeal Mask Airway (FLMA)
Number of subjects: 30
Study 11130130 — intervention group
Group type: COMPARATOR
Intervention: Intubating Laryngeal Mask (ILM)
Number of subjects: 30
Study 8946970 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive model based on age > 55, iron deficiency, and weight loss
Number of subjects: 981
Study 8946970 — intervention group
Group type: EXPERIMENTAL
Intervention: Age > 55, iron deficiency, weight loss
Number of subjects: 981
Study 1463171 — intervention group
Group type: EXPERIMENTAL
Intervention: Prewarmed local anaesthetic solution (37 degrees C)
Number of subjects: 44
Study 1463171 — intervention group
Group type: COMPARATOR
Intervention: Room temperature local anaesthetic solution (25 degrees C)
Number of subjects: 44
Study 6423162 — intervention group
Group type: EXPERIMENTAL
Intervention: Large volume, low pressure endotracheal tube cuffs (Portex Profile, Searle Sensiv, Mallinkrodt Hi‐Lo, Lanz)
Number of subjects: 40
Study 6423162 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuff inflation pressure
Number of subjects: 40
Study 30834686 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure indicators (EIs) collected from imaging departments
Number of subjects: 1422
Study 29378255 — intervention group
Group type: EXPERIMENTAL
Intervention: Qscan device-based learning
Number of subjects: 100
Study 29378255 — intervention group
Group type: COMPARATOR
Intervention: Traditional learning
Number of subjects: 100
Study 26917956 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast in addition to ICS/LABA/LAMA
Number of subjects: 0
Study 24500536 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention 2 (3‐h structured education program with personalized pedometer use)
Number of subjects: 87
Study 24500536 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention 1 (3‐h group‐based structured education program aimed at promoting physical activity)
Number of subjects: 87
Study 24500536 — intervention group
Group type: COMPARATOR
Intervention: Control (advice leaflet)
Number of subjects: 87
Study 24500536 — intervention group
Group type: COMPARATOR
Intervention: Intervention 2 compared to Control
Number of subjects: 87
Study 24500536 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased physical activity at each time point
Number of subjects: 87
Study 22927674 — intervention group
Group type: EXPERIMENTAL
Intervention: SafeCare home-based model
Number of subjects: 354
Study 19282124 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg lopinavir + 50 mg ritonavir tablet formulation
Number of subjects: 36
Study 17975231 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (100 mg/kg i.v. bolus, 20 mg/kg/hr infusion until four hours after cardiopulmonary bypass)
Number of subjects: 177
Study 17975231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177
Study 14561235 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent hypobaric hypoxia (simulated altitude of 4500 m for 90 min, three times a week for 3 weeks)
Number of subjects: 12
Study 14561235 — intervention group
Group type: COMPARATOR
Intervention: Control group (not exposed to intermittent hypoxia)
Number of subjects: 12
Study 14561235 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent hypobaric hypoxia
Number of subjects: 12
Study 11041902 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam 3.75 mg/d
Number of subjects: 774
Study 11041902 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam 7.5 mg/d
Number of subjects: 774
Study 11041902 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam 15 mg/d
Number of subjects: 774
Study 11041902 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 100 mg (50 mg twice daily)
Number of subjects: 774
Study 11041902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 774
Study 8977598 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 800 micrograms twice daily plus terbutaline 1000 micrograms three times daily
Number of subjects: 16
Study 8977598 — intervention group
Group type: COMPARATOR
Intervention: Budesonide 800 micrograms twice daily
Number of subjects: 16
Study 8977598 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide plus terbutaline
Number of subjects: 16
Study 1611833 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycaemic index diet
Number of subjects: 15
Study 6487498 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg
Number of subjects: 7
Study 6487498 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg
Number of subjects: 7
Study 6487498 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 80 mg
Number of subjects: 7
Study 6487498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 30120640 — intervention group
Group type: EXPERIMENTAL
Intervention: BTX-A (200 units injected into the gastric antrum and body)
Number of subjects: 32
Study 30120640 — intervention group
Group type: COMPARATOR
Intervention: Control (0.9% saline injections)
Number of subjects: 32
Study 27492428 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambu
Number of subjects: 105
Study 27492428 — intervention group
Group type: EXPERIMENTAL
Intervention: I-gel
Number of subjects: 105
Study 27492428 — intervention group
Group type: COMPARATOR
Intervention: LMA-S
Number of subjects: 105
Study 25771831 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose-free milk
Number of subjects: 40
Study 25771831 — intervention group
Group type: COMPARATOR
Intervention: Regular infant formula (Control)
Number of subjects: 40
Study 24756739 — intervention group
Group type: EXPERIMENTAL
Intervention: Mat Pilates programme (8 weeks, 3 times weekly)
Number of subjects: 50
Study 24756739 — intervention group
Group type: COMPARATOR
Intervention: Control group (maintained normal daily activities)
Number of subjects: 50
Study 20660010 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine 25 mg
Number of subjects: 48
Study 20660010 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine 50 mg
Number of subjects: 48
Study 20660010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 19323660 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgenic alopecia group
Number of subjects: 97
Study 19323660 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=87)
Number of subjects: 97
Study 17026493 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic insulin aspart 30 (BIAsp30)
Number of subjects: 23
Study 16750496 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 Gy radiotherapy given in 25 fractions
Number of subjects: 1410
Study 16750496 — intervention group
Group type: EXPERIMENTAL
Intervention: 39 Gy given in 13 fractions
Number of subjects: 1410
Study 16750496 — intervention group
Group type: EXPERIMENTAL
Intervention: 42.9 Gy given in 13 fractions
Number of subjects: 1410
Study 10673518 — intervention group
Group type: COMPARATOR
Intervention: Fludarabine (FLU) alone
Number of subjects: 199
Study 10673518 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine plus idarubicin (FLU-ID)
Number of subjects: 199
Study 8640997 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic therapy (hydrochlorothiazide plus amiloride)
Number of subjects: 12
Study 8640997 — intervention group
Group type: COMPARATOR
Intervention: Placebo transdermal nitroglycerin
Number of subjects: 12
Study 1639045 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycogen depletion treatment (exercise + low-carbohydrate high-fat diet)
Number of subjects: 8
Study 1639045 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycogen repletion treatment (exercise + high carbohydrate diet)
Number of subjects: 8
Study 1639045 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet treatment (low-carbohydrate high-fat diet alone)
Number of subjects: 8
Study 6440460 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% glucose
Number of subjects: 27
Study 6440460 — intervention group
Group type: COMPARATOR
Intervention: 50% fat 50% glucose
Number of subjects: 27
Study 29143934 — intervention group
Group type: EXPERIMENTAL
Intervention: KAMUT® khorasan products
Number of subjects: 30
Study 29784190 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted laparoscopic radical cystectomy (RARC)
Number of subjects: 118
Study 29784190 — intervention group
Group type: COMPARATOR
Intervention: Open radical cystectomy (ORC)
Number of subjects: 118
Study 26954669 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous supraclavicular block
Number of subjects: 75
Study 26954669 — intervention group
Group type: COMPARATOR
Intervention: Continuous interscalene block
Number of subjects: 75
Study 24327422 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for spinal metastasis post-RCT
Number of subjects: 7404
Study 21904945 — intervention group
Group type: EXPERIMENTAL
Intervention: Health maintenance reminders via a secure PHR 'eJournal'
Number of subjects: 3979
Study 21904945 — intervention group
Group type: COMPARATOR
Intervention: Active control arm with access to an eJournal for medications, allergies, and diabetes management
Number of subjects: 3979
Study 19042044 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/d atorvastatin (statin group 1)
Number of subjects: 119
Study 19042044 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/d atorvastatin (statin group 2)
Number of subjects: 119
Study 19042044 — intervention group
Group type: COMPARATOR
Intervention: Control group (no atorvastatin)
Number of subjects: 119
Study 18779613 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan plus carboplatin (IC)
Number of subjects: 209
Study 18779613 — intervention group
Group type: COMPARATOR
Intervention: Oral etoposide plus carboplatin (EC)
Number of subjects: 209
Study 15925032 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasally administered Cholecystokinin (CCK)
Number of subjects: 0
Study 15925032 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 0
Study 12872017 — intervention group
Group type: EXPERIMENTAL
Intervention: High-velocity resistance training
Number of subjects: 30
Study 12872017 — intervention group
Group type: COMPARATOR
Intervention: Low-velocity resistance training
Number of subjects: 30
Study 10550374 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with three cycles of carboplatin/5-FU prior to surgery and radiotherapy (arm A)
Number of subjects: 144
Study 10550374 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment with surgery and radiotherapy (arm B)
Number of subjects: 144
Study 8908387 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal insulin injection (0.15 units/kg body wt)
Number of subjects: 8
Study 8908387 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous insulin injection (0.15 units/kg body wt)
Number of subjects: 8
Study 1858956 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg)
Number of subjects: 18
Study 1858956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 31190192 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive training program using sleep position trainer (SPT)
Number of subjects: 38
Study 31190192 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual training program using sleep position trainer (SPT)
Number of subjects: 38
Study 31190192 — intervention group
Group type: COMPARATOR
Intervention: Both training modalities (intensive and gradual)
Number of subjects: 38
Study 28207516 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly SMS interventions
Number of subjects: 2
Study 26481293 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-flux hemodialysis (LF-HD)
Number of subjects: 28
Study 26481293 — intervention group
Group type: COMPARATOR
Intervention: High-flux hemodialysis (HF-HD)
Number of subjects: 28
Study 23381211 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40mg/day (E40)
Number of subjects: 570
Study 23381211 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20mg/day (E20)
Number of subjects: 570
Study 23381211 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20mg/day (O20)
Number of subjects: 570
Study 21074000 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance-based coping
Number of subjects: 48
Study 21074000 — intervention group
Group type: COMPARATOR
Intervention: Control coping strategies
Number of subjects: 48
Study 21129337 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose (5 g glucose, 0.5 U insulin)
Number of subjects: 16
Study 21129337 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium dose (10 g glucose, 1 U insulin)
Number of subjects: 16
Study 21129337 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose (20 g glucose, 2 U insulin)
Number of subjects: 16
Study 21129337 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses tested
Number of subjects: 16
Study 17237317 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary and behavioral counseling to support adherence to trial dietary goals.
Number of subjects: 833
Study 15522382 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency-doubling perimetry in patients with diabetes
Number of subjects: 50
Study 15522382 — intervention group
Group type: COMPARATOR
Intervention: Frequency-doubling perimetry in nondiabetic normal controls
Number of subjects: 50
Study 11856075 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide enema (2 mg/100 mL at bedtime)
Number of subjects: 26
Study 11856075 — intervention group
Group type: COMPARATOR
Intervention: Oral metronidazole (0.5 g b.d.)
Number of subjects: 26
Study 11856075 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide enema
Number of subjects: 26
Study 11856075 — intervention group
Group type: COMPARATOR
Intervention: Oral metronidazole
Number of subjects: 26
Study 9642517 — intervention group
Group type: EXPERIMENTAL
Intervention: C2: 200-400 ng/ml
Number of subjects: 30
Study 9642517 — intervention group
Group type: COMPARATOR
Intervention: C0: 100-200 ng/ml
Number of subjects: 30
Study 8608684 — intervention group
Group type: EXPERIMENTAL
Intervention: Aceclofenac (100 mg twice daily)
Number of subjects: 397
Study 8608684 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac (50 mg three times daily)
Number of subjects: 397
Study 8608684 — intervention group
Group type: EXPERIMENTAL
Intervention: Aceclofenac
Number of subjects: 397
Study 8608684 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac
Number of subjects: 397
Study 2681495 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium meclofenamate (Meclomen) 100 mg, p.os, t.i.d.
Number of subjects: 24
Study 2681495 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 956103 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg ascorbic acid
Number of subjects: 60